市场调查报告书
商品编码
1426120
全球免疫分析市场评估:依产品、技术、分析物、应用、最终用户、地区、机会、预测(2017-2031)Immunoassay Market Assessment, By Product, By Technique, By Specimen, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
全球免疫分析市场规模预计将从 2023 年的 341.1 亿美元增至 2031 年的 496.3 亿美元,2024-2031 年预测期间复合年增长率为 4.8%。Masu。 全球免疫分析市场的成长受到多种因素的推动,例如慢性病和传染病的流行、老年人口的增加、生物技术行业的技术进步和创新、医疗保健支出的增加以及政府举措。
由于全球心血管疾病、糖尿病和癌症等慢性疾病的盛行率不断上升,全球免疫分析市场呈现强劲成长。 久坐的生活方式、不健康的饮食以及饮酒和吸烟的增加是慢性病患者数量不断增加的主要危险因素。 传染病的增加也加速了市场的成长。 这是因为免疫测定在多种疾病的检测和监测中发挥重要作用。 人口老化加剧是传染病和慢性病最常见的危险因子之一。 免疫测定是从筛检和定期监测的角度准确、快速诊断这些疾病的重要工具。 为了提供优质的医疗保健和升级医疗设施,政府鼓励私人公司投资于研发(R&D),以获得更有效和高效的免疫分析平台和技术。 此外,免疫分析在医院、诊所和生技公司等各医疗部门的广泛使用也显着增加了对免疫分析诊断的需求。
慢性病和传染病流行
慢性病和传染病的流行正在推动全球免疫分析市场的发展。 随着这些疾病的盛行率持续上升,用于诊断和监测各种疾病的免疫测定的需求不断增加。 这促进了创新产品的开发,并增加了基于免疫分析的现场护理 (POC) 和快速检测的采用。 免疫测定用于诊断各种传染病,如水痘、登革热、伊波拉出血热、流感和肝炎。 它是检测临床样本中是否有特定病毒、病毒抗原和抗体的宝贵工具。 卫生专业人员只有透过早期诊断和准确检测疾病及其病原体才能有效解决此问题,以指导适当的治疗。
例如,rRT-PCR 在 SARS-CoV-2 感染过程中发挥了重要作用,预计免疫检测在未来的大流行中将更加必要。 随着疾病负担的增加,对免疫分析的需求也在增加,推动了全球免疫分析市场的成长。技术进步
近年来,生技领域的技术进步令人瞩目,免疫分析市场的技术创新也不断进步。 透过提高免疫测定特异性的新技术和方法,这些进步旨在提高测试的特性和潜力,最终实现更好的疾病诊断和治疗。 例如,2022 年在 Biosensors 上发表的一篇题为 "奈米技术和生物技术的进展" 的论文描述了一种被称为 "奈米□(BD1)" 的独特□的独特□特性。 这些奈米□具有不同的催化机制,可以设计为建构模拟□的免疫测定法的标籤,并提高检测灵敏度和选择性。 奈米□表现出高可调的催化活性、易于製备、稳定性高且成本低廉。 由于这些因素,奈米□比天然□更受欢迎,因为它们可以克服天然□的缺点。 这些在提高免疫测定灵敏度方面的进步进一步推动了全球免疫测定市场的成长。
本报告针对全球免疫分析市场进行研究与分析,提供市场规模与预测、市场动态、主要参与者现况及前景等。
Global immunoassay market is projected to witness a CAGR of 4.8% during the forecast period 2024-2031, growing from USD 34.11 billion in 2023 to USD 49.63 billion in 2031. Growth in the global immunoassay market is driven by various factors such as the rising prevalence of chronic diseases and infectious diseases, the growing elderly population, technological advancements and innovations in the biotech industry, increased healthcare expenditure, and government initiatives.
The global immunoassay market is undergoing robust growth due to the growing prevalence of chronic diseases around the world, such as cardiovascular diseases, diabetes, and cancer. A sedentary lifestyle, unhealthy diet, and increasing alcohol and tobacco consumption are the main risk factors that are contributing to the growing number of patients with chronic diseases. An increasing number of infectious diseases are also accelerating the growth of the global immunoassay market, as immunoassay has an important role in detecting and monitoring several diseases. Increase in elderly population is one of the most common risk factors for chronic as well as infectious diseases, as elderly people are more prone to these diseases. Immunoassay is an important tool for accurate and fast diagnosis of these diseases in terms of screening and regular monitoring. To deliver high-quality medical care and upgrade healthcare facilities, governments are encouraging private companies to invest more in research and development (R&D) of more effective and efficient immunoassay platforms and technologies. Moreover, wide applications of immunoassay in different healthcare sectors like hospitals, clinics, biotechnology companies are significantly increasing the demand for immunoassay diagnostics.
Increasing Prevalence of Chronic and Infectious Diseases
The increasing prevalence of chronic and infectious diseases drives the global immunoassay market. As the incidence of these diseases continues to rise, there is a growing demand for immunoassays to diagnose and monitor various conditions. This has led to the development of innovative products and the adoption of immunoassay-based point-of-care (POC) testing and rapid testing. Immunoassay is used to diagnose a variety of infectious diseases, including chickenpox, dengue, ebola, influenza, and hepatitis. It is a valuable tool for detecting the presence of specific viruses, viral antigens, or antibodies in clinical specimens. Healthcare professionals can only effectively address this issue by guiding the appropriate treatment through early diagnosis and accurate detection of the disease and its causing agent.
For instance, rRT-PCR played a crucial role during SARS-CoV-2 infection, and it is expected that immunoassay will further be required in future pandemics. With growing burden of these diseases, demand for immunoassay is also increasing, facilitating growth of global immunoassay market.
Technological Advancements
Over the past few years, there has been a surge of favorable technological advancements in the biotechnology sector, which, in turn, has also led to innovation in the immunoassay market. With novel techniques and methods to improve the immunoassay's specificity, these advancements aim to improve the characteristics and potential of the test, which may ultimately lead to better disease diagnosis and treatment. For instance, an article titled "The advancement in nanotechnology and biotechnology", published in Biosensors journals in the year 2022, described the invention of a new type of nanomaterial with intrinsic enzyme-like characteristics known as "nanozymes[BD1]". These nanozymes have different catalytic mechanisms, mimic enzymes, and can be designed as labels in constructing immunoassays to improve detection sensitivity and selectivity. Nanozymes exhibit high catalytic activity with tunability, easy preparation, high stability, and low cost. Due to these factors, nanozymes are gaining significant traction over natural enzymes, as they also eliminate the latter's defects. These advancements to improve immunoassays sensitivity further propel the growth of global immunoassay market.
Government Initiatives
Immunoassays are valuable tools used for various purpose such as disease diagnosis, research and development in biopharmaceuticals, including vaccines and gene and cell therapy, and drug monitoring. Due to its wide applications, governments around the globe have initiated several policies and programs, emphasizing the importance of technological advancements and improvements in immunoassay technique quality. Governments are investing billions of dollars in R&D to bring innovation in modern immunoassay diagnostic techniques.
For instance, in September 2023, the National Institute of Justice (NIJ) announced funding of $1.9 million to support forensic science research under its Public Labs R&E program. This funding helps NIJ to improve the examination and analysis of the most efficient, reliable, accurate, and cost-effective methods of analysis in the public forensic labs, including the development of a method for product and biological tissue analysis and assess cross-reactivity of immunoassay.
Increasing Volume of ELISA
Enzyme-linked immunosorbent assay (ELISA) is one of the most widely used immunoassay methods against HCoVs (Human Coronaviruses) and other viruses. Due to its ease of use with simple procedure, high throughput, rapid, high sensitivity, and good specificity, ELISA is gaining popularity among the major players. ELISA is a safe, eco-friendly, and cost-effective essay diagnostic procedure. Due to this, many major players are launching innovative techniques in ELISA to improve their product portfolios.
For instance, in October 2023, QIAGEN launched QuantiFERON-EBV RUO. This was designed to support research and development in EBV infection (Ebola Virus) and EBV-related malignancies. It uses QuantiFERON technology, along with ELISA detection system, to enable the researcher to study the immune response in the virus, which will further assist in improving the medical treatment against these viruses. These new launches and innovations in immunoassays are driving the global immunoassay market.
Growing Applications of Immunoassay
Immunoassay tests have a vast area of applications, including medical diagnostics, environmental testing, and food safety. Immunoassay tests are used for diagnosing infectious diseases, such as HIV, hepatitis, and tuberculosis, screening and monitoring for drugs abuse, and identifying and measuring allergens in food and environmental samples. They also gain traction as they provide rapid and accurate diagnostic results for point-of-care testing in different healthcare settings. Due to this, many market players are launching novel products in immunoassays to enhance their diagnostic products portfolio.
For instance, in May 2023, Beckman Coulter, a leader in clinical diagnostics, launched DxI 9000 Access Immunoassay Analyzer. This product has the potential to run up to 215 tests per hour. This technology has zero daily maintenance and will enable the healthcare professionals to improve throughput rates with great precision.
Future Market Scenario (2024-2031F)
Global immunoassay market is expected to grow tremendously in the coming years due to multiple factors. One of the primary drivers include an increasing prevalence of chronic and infectious diseases and a growing geriatric population. This will be further supported by rapid technological advancements and the integration of AI, resulting in accurate diagnosis and improved accuracy, especially for community-level surveillance. Moreover, government initiatives, policies, and programs are expected to enhance screening, which, in turn, will create a favorable market outlook. In line with this, increasing investments by public and private companies for research and development in their respective markets and collaborative ventures involving diagnostic device manufacturers and research institutions have spurred innovation leading to further growth of the global immunoassay market.
Key Players Landscape and Outlook
In the immunoassay industry, several public and private organizations are actively establishing strategic partnerships and distribution agreements to empower and strengthen each other's resources, gain insights regarding new markets and advanced technologies, and expand their businesses across the globe. Many big players are undergoing mergers and acquisitions, and partnerships to enhance and strengthen their product portfolios. For instance, on July 2023, Beckman Coulter Diagnostics, which is a leader in clinical diagnostics, and Fujirebio, a pioneer in neurological markers and a leader in manufacturing In Vitro Diagnostic (IVD), announced a new strategic partnership to combine their respective immunoassay strengths to support clinical trials, therapeutic development, reimbursement, and routine clinical adoption in neurodegenerative diseases.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work